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Introduction: Polymerase chain reaction (PCR)-based techniques to detect Mycobacterium
tuberculosis DNA in respiratory specimens have been increasingly used to diagnose pulmonary
tuberculosis. Their use in non-respiratory specimens to diagnose extrapulmonary tuberculosis
is, however, controversial. In this study, we estimated the accuracy of three in-country
commercialized PCR-based diagnostic techniques in pleural fluid samples for the diagnosis of
pleural tuberculosis.
Methods: Patients underwent thoracenthesis for diagnosis purposes; pleural fluid aliquots
were frozen and subsequently submitted to two real time PCR tests (COBASTAQMANMTB
and XpertMTB/Rif) and one conventional PCR test (Detect-TB). Two different reference
standards were considered: probable tuberculosis (based on clinical grounds) and confirmed
tuberculosis (bacteriologically or histologically).
Results: Ninety-three patients were included, of whom 65 with pleural tuberculosis, 35 of
them confirmed. Sensitivities were 29% for COBASTAQMANMTB, 3% for XpertMTB/Rif and
3% for Detect-TB; specificities were 86%, 100% and 97% respectively, considering confirmedSobrinho, 74/203, Humaita´, 22271-080 Rio de Janeiro, Brazil. Tel.: þ55 21 39989194.
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PCR for diagnosing pleural tuberculosis 919tuberculosis. Considering all cases, sensitivities were 16%, 3% and 2%, and specificities, 86%,
100%, and 97%.
Discussion: Compared to the 95% sensitivity of adenosine deaminase, the most sensitive test
for pleural tuberculosis, the sensitivities of the three PCR-based tests were very low. We
conclude that at present, there is no major place for such tests in routine clinical use.
ª 2014 Elsevier Ltd. All rights reserved.Introduction
Tuberculosis is still a leading cause of death worldwide, and
Brazil is one of the 22 countries with the highest burden of
the disease [1]. Pleural tuberculosis is the second most
common form of the disease [2,3], and its diagnosis remains
a challenge [4]. Sensitivity of smears for acid-fast bacilli
(AFB) is extremely low (<5%) [4e6], cultures have a long
delay and also low sensitivity (<60%) [7e10]. Histopatho-
logical examination of the pleural tissue is the most sensi-
tive diagnostic test (80e85%) [4,6,10,11]; however, it
requires a pleural biopsy, a procedure that increases risks
and costs [11]. The adenosine deaminase (ADA) enzyme is
another pleural fluid marker of tuberculosis. Despite its
high sensitivity (56e100%) [12e14], ADA activity reflects
only a non-specific immunologic response [11]. Previous
studies showed a poor positive predictive value of ADA for
tuberculosis diagnosis in low-tuberculosis incidence set-
tings [12,14]. Despite these limitations, in practice, ADA,
AFB and cultures of pleural fluid as well as pleural biopsies
have been recommended as the reference tests for diag-
nosing pleural tuberculosis [4,11,12,14,15].
After a century of stagnation regarding new technolo-
gies for the diagnosis of tuberculosis, new molecular-
based technologies were approved for the detection of
Mycobacterium tuberculosis DNA in respiratory specimens
in the past two decades, and automated systems, such as
the XpertMTB/Rif, commercially available in the last
couple of years, are being rapidly incorporated for the
diagnosis of pulmonary tuberculosis in high-burden coun-
tries [16e18]. However, their use in extrapulmonary
samples is still controversial [19]. In-house PCR-based
tests in pleural fluid have a high specificity (98%), but low
and heterogenous sensitivity (43e77%), but automated
systems were less studied [20]. In order to study the
usefulness of PCR technique in the diagnosis of pleural
tuberculosis in routine practice, in the present study, we
aimed to evaluate the accuracy of three commercially
available tests: two real time PCR tests
(COBASTAQMANMTB and XpertMTB/Rif) and one con-
ventional PCR test (Detect-TB).
Methods
From September 2007 to March 2011, all patients with a
pleural effusion needing a thoracenthesis for diagnostic
purposes hospitalized in the 7th ward (an Internal Medi-
cine Unit) of Hospital Geral da Santa Casa da Miserico´rdia
do Rio de Janeiro were eligible. Adults (>18 years old)were invited to participate and those who signed an
informed consent were prospectively included. Patients
were excluded if they had bleeding disorders contra-
indicating thoracenthesis, if the fluid volume was insuffi-
cient for storage or if a final diagnosis could not be
ascertained.
In this pragmatic study, diagnosis and management were
carried out according to the clinicians’ practice and Bra-
zilian Guidelines [21]. Consent was obtained for the
experimental (PCR) techniques only. Pleural fluid was for-
warded for biochemical (protein, glucose and ADA level),
for cytometric (total white cells, mononuclear, neutro-
phils), for bacteriological (AFB smears and M. tuberculosis
culture in liquid media e BACTEC mycobacterial growth
indicator tube [MGIT] 960 System, BD) and sporadically,
Gram stain and culture for pyogenic bacteria evaluation.
Pleural tissue, obtained with a Cope needle, was forwarded
for histopathological analysis and for M. tuberculosis cul-
ture (MGIT). Aliquots were frozen at 80 C. Spontaneous
or induced sputum specimens were also forwarded for AFB
and culture, when available (data not shown). According to
the Brazilian Guidelines [21], the diagnosis of confirmed
tuberculosis was made if any specimen was positive for AFB
or culture, or if granuloma with or without caseous necrosis
was present on a biopsy. A clinical diagnosis of probable
tuberculosis was made if patients had symptoms compat-
ible with tuberculosis (fever, night sweats and weight loss),
an exudative pleural fluid or an ADA level > 40 IU/L and if
they had clinical improvement after antituberculous ther-
apy. Patients were clinically managed according to these
results.
For the three PCR techniques, samples were simulta-
neously unfrozen in 2012 and processed according to the
manufacturer’s recommendations (except for the freezing
step) by two experienced lab technicians (EFSSKO and
SEM), blinded to the clinical results. In brief,
COBASTAQMANMTB amplifies and detects the rRNA 16S
gene sequence [22e24], Xpert MTB/Rif automatically
amplifies and detects the rpo b gene [25], and the con-
ventional Detect-TB amplifies and detects the IS 6110
insertion [26].
To assess the similarity between groups of participants
Wilcoxon non-parametric test was used for medians. Pro-
portions were compared using the Fischer’s exact test.
Sensitivities, specificities and their 95% confidence in-
terval (CI) were calculated for each test using (i) the
confirmed cases as the reference standard and (ii) all cases
(confirmed and probable) as the second reference stan-
dard, according to the Standards for Reporting of Diagnostic
Accuracy Studies (STARD) initiative recommendations [27].
Table 1 Characteristics of eligible participants submitted
to investigation of a pleural effusion.
Included Not included P value
920 A. Trajman et al.Sensitivities were compared among those with the final
diagnosis of tuberculosis using the c2 McNemar test. Spec-
ificities could not be compared since, by definition, there
are no false-positive for tuberculosis tests [28].N Z 93 N Z 98a
Median age (IQR) 50 (40; 57) 43 (27; 61) 0.08
Sex 0.75
Female 19 (20%) 19 (19%)
Male 74 (80%) 79 (81%)
HIV 0.37
Positive 5 (5%) 10 (10%)
Negative 61 (66%) 65 (66%)
Unknown 27 (29%) 23 (24%)
Tuberculosisb 0.18
Yes 63 (68%) 69 (77%)
No 30 (32%) 20 (23%)
IQR e interquartile range.
aEthics
The study was in accordance with the Brazilian CNS 196/96
(at present replaced by 466/12) and 441/11 resolutions,
which follow the Helsinki declaration regarding human
being research rights. It was authorized by the institutional
review board of the Hospital Geral da Santa Casa da Mis-
erico´rdia do Rio de Janeiro, the latest version was also
approved by the National Ethical Committee (#771/2009).
Only patients accepting to sign the informed consent,
which foresaw freezing and further processing of samples,
were included.Among 21 participants without a final diagnosis, 12 did not
have available information on clinical characteristics.
b 9 patients without a final diagnosis were excluded from this
analysis.
Results
Out of 203 eligible patients, 110 were excluded: 21 did not
have a final diagnosis and 89 did not have sufficient fluid to
store (Fig. 1). Their sex, age, HIV-status and proportion of
tuberculosis were similar to the included patients (Table 1),
although they tended to be younger. Out of the 93 included
patients, 63 (68%) had a final diagnosis of pleural tubercu-
losis, of whom 35 (56%) were confirmed. Other diagnoses
are summarized in Fig. 1.
Participants’ characteristics according to final diagnosis
are compared in Table 2. Patients with tuberculosis were
younger. In Tables 3A and 3B, test results based on which
diagnosis was performed as well as experimental (PCR) testFigure 1 Flowchart ofresults are displayed. Missing results are due to temporary
unavailability of consumables in the hospital or to absence
of pleural tissue in biopsy specimens, since this was a
pragmatic study. Gram staining and culture for pyogenic
bacteria were performed in 54% of participants. Despite
two positive gram stains (one in a patient with a final
clinical diagnosis of tuberculosis and the other in a patient
with a final diagnosis of Meigs’ Syndrome), all cultures for
non-specific bacteria were negative.
As shown in Tables 3A and 3B, the three PCR-based tests
had a very low sensitivity, although COBASTAQMANMTBstudy participants.
Table 2 Characteristics of pleural TB suspects included in













45 (35; 53) 46,5 (32; 57) 56 (49; 62) <0.01
Sex <0.01
Female 1 (3%) 10 (36%) 8 (27%)
Male 34 (97%) 18 (64%) 22 (73%)
HIV 0.05
Positive 4 (12%) 1 (4%) 0 (0%)
Negative 20 (57%) 23 (82%) 18 (60%)
Unknown 11 (31%) 4 (14%) 12 (40%)
IQR e interquartile range, TB e tuberculosis.
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(pZ 0.02) and Detect-TB (pZ 0.02). Conversely, ADA had
the highest sensitivity, followed by the histopathological
examination. The three PCR tests had a significantly lower
sensitivity when compared to ADA (p < 0.01) and to the
histopathological examination (p < 0.01).
Specificities of XpertMTB/RIF and Detect-TB were the
highest, 100% (89e100%) and 97% (81e100%, respectively).
Among 17 hemorrhagic samples, nine had false-negative
results and four had indeterminate results in at least one of
the three PCR-based tests.Discussion
In this pragmatic, routine study, sensitivities of three PCR-
based commercially available tests for diagnosing pleural
tuberculosis were very low. Despite their excellentTable 3A Sensitivity and specificity of tests: 3A e Only patients
Tests N True positive results
among TB patients
PF AFB smearb 65 1








Xpert MTB/Rifh 59 1
ADA e Adenosine deaminase, PCR e polymerase chain reaction, PF e
a Analysis of 35 patients with confirmed TB and 30 patients with ot
b Acid-fast bacilli smear in pleural fluid.
c Pleural fluid culture was not performed in two patients.
d Histopathological examination in pleural tissue was not done in 15
e Adenosine deaminase (ADA) measurement in pleural fluid was not p
were higher than 40 IU/L.
f Detect-TB-One patient did not have enough fluid to perform the
g COBAS TAQMAN MTB-Six patients had invalid results.
h Xpert MTB/Rif-One patient did not have enough material and fivspecificities, the low sensitivities make them unsuitable for
routine use in clinical practice, unless if used as a confir-
matory test after triage with more sensitive tests, such as
ADA. Cost-effectiveness studies for this approach would,
however, be necessary, since it would be unlikely that this
strategy would be cost-effective, due to the high costs of the
tests and the relatively low cost of tuberculosis treatment.
The very low sensitivities found in our study contrast
with previous results in the literature, as reviewed by Pai
et al., and with our own results in a previous series, using
an in house PCR technique. Most series reviewed in Pai’s
meta-analysis [20] used in house tests and thus did not
include automated tests, sensitivities varied from 25% to
up to 87%. A more recent meta-analysis that evaluated
the accuracy of XpertMTB/RIF in 1385 pleural fluid
samples confirmed a low pooled sensitivity (43.7%; 95% CI
24.8%; 64.7%) and a high pooled specificity (98.1%; 95% CI
95.3%; 99.2%) if culture for MTB was used as the reference
standard. Using a composite standard reference (histo-
pathological examination, clinical signs and AFB smear),
sensitivity was reduced to levels similar to those found in
the present study (17%; 95% CI 7.5%; 34.2%) [29].
One of the possible reasons for the low sensitivity of
PCR-based tests is that pleural effusions are thought to be
due to a local inflammatory reaction. However, even among
those with bacteriologically confirmed tuberculosis, PCR
tests were mostly negative in our study.
Another possible explanation for the very low sensitiv-
ities in our study was the presence of inhibitory substances.
We did not submit clinical specimens to any processing prior
to the technique itself. Blood and other inhibitors, such as
heparin or pus may interfere with cell lysis, inactivating the
DNA polymerase or interfering with nucleic acids [30]. This
can cause false-negative or invalid results, as seen in our
sample [11,30]. Eliminating inhibitory substances in clinical
specimens has been reported to increase the sensitivity ofwith confirmed diagnosis (confirmed TB and other diagnosis).a




3% (0%; 16%) e e
47% (31%; 64%) e e
90% (73%; 97%) e e
95% (76%; 100%) 20 87% (67%; 96%)
3% (0%%; 19%) 28 97% (81%; 100%)
29% (16%; 47%) 24 86% (68%; 95%)
3% (0%; 17%) 26 100% (89%; 100%)
pleural fluid, 95% e CI confidence interval, TB e tuberculosis.
her confirmed diagnosis (see Fig. 1).
patients.
erformed in 21 patients. ADA positive was considered when results
test and two other patients had invalid results.
e other patients had invalid results.
Table 3B Sensitivity and specificity of tests: 3B e All patients included in the study (confirmed or probable pleural tuber-
culosis and other diagnosis).a









PF AFB smearb 93 1 2% (0%; 9%) e e
PF culturec 91 16 26% (16%; 38%) e e
Pleural histopathological
examinationd
62 26 63% (48%; 76%) e e
PF ADAe 62 35 90% (76%; 97%) 20 87% (67%; 96%)
PF PCR
Detect-TBf 90 1 2% (0%; 10%) 28 97% (81%; 100%)
COBAS TAQMAN MTBg 84 9 16% (8%; 28%) 24 86% (68%; 95%)
Xpert MTB/Rifh 85 2 3% (0%; 12%) 26 100% (89%; 100%)
ADA e Adenosine deaminase, PCR e polymerase chain reaction, PF e pleural fluid, 95% e CI confidence interval, TB e tuberculosis.
a Analysis of 63 patients with clinical TB and 30 patients with other confirmed diagnosis (see Fig. 1).
b Acid-fast bacilli smear in pleural fluid.
c Pleural fluid culture was not performed in two patients.
d Histopathological examination in pleural tissue was not done in 31 patients.
e Adenosine deaminase (ADA) measurement in pleural fluid was not performed in 31 patients. ADA positive was considered when results
were higher than 40 IU/L.
f Detect-TB-One patient did not have enough fluid to perform the test and two other patients had invalid results.
g COBAS TAQMAN MTB-Nine patients had invalid results.
h Xpert MTB/Rif-One patient did not have enough material and seven other patients had invalid results.
922 A. Trajman et al.PCRs. Likewise, concentrating the clinical specimen might
yield better results [6,31e33].
Finally, the low sensitivities found in our study could also
be explained by the long storage time in freezers, despite
the optimal temperature (e80 C). Indeed, fresh samples
have a better sensitivity 50% (95% CI 36%; 64%) than frozen
specimens (26%; 95% CI 14%; 40%) [17]. Manufacturers
recommend the use of tests in specimens frozen for up to 6
months or refrigerated for up to 4e10 days. Some of our
specimens were frozen for up to 4 years. However, no
relationship was seen between false-negatives and date of
specimen collection (data not shown).
One of the main limitations of our study was the high
number of presumptive (non-confirmed) cases. This was
due to the routine, pragmatic nature of the study, con-
ducted in a public secondary health facility. Culture of
pleural tissue, which could significantly improve accuracy
of diagnosis, were not performed. In addition, many pa-
tients did not have one of the routine tests. However, even
among confirmed cases, sensitivity was unacceptably low,
confirming the findings of the systematic reviews. Another
important limitation was the use of frozen specimens.
Conversely, the main strength of the study is that every
sample, in routine conditions, was processed, comparing
three different commercially available kits.
In summary, despite the high specificity, because of
their very low sensitivities, it is unlikely that PCR-based
tests will have a major clinical usefulness for the diagnosis
of pleural tuberculosis.
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